IGF-1 LR3

IGF-1 LR3 is a modified form of insulin-like growth factor-1 (IGF-1), a hormone that normally circulates bound to carrier proteins. The LR3 change reduces that binding, so more of the analog stays free to activate cell-surface receptors Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

This design has made it a tool in research on tissue engineering, brain aging, fetal development, and muscle. When added to cultured human skin cells, it increased collagen fiber density and improved the strength of the grown tissue IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering. In mice, intranasal delivery changed the structure of brain amyloid plaques, but did not preserve memory or learning Intranasal Long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex, but fails to preserve cognitive function in male 5XFAD mice. Other animal studies have explored local delivery for nerve regrowth and muscle loss Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers+1.

Community interest often centers on muscle growth and recovery. While the receptor pathways it turns on are clearly anabolic, controlled human trials for these outcomes are absent. All current evidence for muscle or performance effects comes from animal models and practitioner reports.

IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a tyrosine kinase that sits on the surface of many cell types. Once activated, the receptor fires two main intracellular pathways: PI3K-Akt-mTOR and MAPK/ERK. The first drives protein synthesis and cell growth, while the second influences cell division and survival Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Because LR3 avoids the normal carrier proteins that mop up native IGF-1, its signal lasts longer. In the skin, this prolonged signaling prompts fibroblasts to ramp up collagen production and organize a tougher extracellular matrix IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering. In the brain, it shifts how microglial cells handle amyloid, but that has not yet translated to cognitive gains Intranasal Long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex, but fails to preserve cognitive function in male 5XFAD mice.

A less obvious effect is on insulin and glucose. Infusion of IGF-1 LR3 into fetal sheep lowered circulating insulin and dampened the insulin response to a glucose challenge. This tells us that strong stimulation of the IGF-1 receptor can feed back onto the pancreatic beta-cells and alter systemic energy handling — a reason hypoglycemia is the most common practical concern with this peptide IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep+1.

Collagen and skin — The strongest human-tissue evidence shows IGF-1 LR3 increases collagen deposition by dermal fibroblasts in a dose-dependent fashion. In one reconstructed tissue model, it thickened the dermal layer and raised the force needed to tear it, even for cells from older donors IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering.

Brain amyloid — Long-term intranasal dosing in an Alzheimer’s mouse model shifted amyloid plaques toward a more compact, possibly less toxic form but did not improve behavior or cognition Intranasal Long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex, but fails to preserve cognitive function in male 5XFAD mice. This has kept interest alive but cautious.

Muscle — In a rat model of volumetric muscle loss, a high-dose implant increased the weight of the remaining muscle without restoring torque, fiber size, or overall function Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers. Simple anabolic receptor activation may not fix severe structural deficits.

Nerve repair — A scaffold that slowly released IGF-1 LR3 in a rat sciatic nerve gap performed as well as an autograft in some measures, but the peptide was only one component of the intervention Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.

Fetal growth — In growth-restricted fetal sheep, direct infusion did not increase overall body growth and actually lowered circulating amino acids, including the branched chains needed for protein synthesis IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.

Published protocols are varied and domain-specific. For dermal tissue engineering, continuous exposure of human fibroblast cultures to 0.5–1 µg/mL over 10–28 days produced measurable collagen gains IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering. In mice, intranasal doses of 50 µg given four times weekly for seven months were used to study brain plaque remodeling Intranasal Long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex, but fails to preserve cognitive function in male 5XFAD mice.

For systemic effects, no optimized human trial exists. Community-based regimens typically start with 20–30 mcg once daily and titrate up to 40–80 mcg, sometimes splitting the dose. Cycles usually run 4–8 weeks, followed by an off-period of equal length. Practitioners often time injections away from large carbohydrate meals to reduce the risk of glucose drops, and many prefer a peri-workout window when the goal is muscle support.

Localized injury protocols employ similar total doses but inject closer to the target area. The interactive protocol card above illustrates one common research-style dosing pattern.

IGF-1 LR3 arrives as a dry powder in a sterile vial. To prepare it for use, the powder is dissolved in a compatible liquid. Bacteriostatic water is most common for research that requires multiple draws from the same vial; it contains a preservative that slows bacterial growth. Sterile water for injection can be used when the entire vial will be used quickly.

Mix by gently swirling. Do not shake. After the powder dissolves, store the vial in the refrigerator at 2–8 °C. A refrigerated, preserved solution is generally considered usable for 21–30 days, while a solution made with sterile water should be discarded after 7–14 days. Never freeze the mixed solution.

The interactive calculator below provides volume-to-dose conversions for any vial size and dilution. Because IGF-1 LR3 is often used in microgram amounts, choosing a dilution that keeps the injection volume reasonable makes accurate measurement easier.

Blood sugar lowering agents — IGF-1 LR3 itself can drop glucose, and adding insulin, sulfonylureas, or even metformin can compound this. Fasting glucose monitoring is essential when these are combined IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep+1.

GH secretagogues — Compounds like CJC-1295, ipamorelin, and MK-677 raise natural IGF-1 levels. Stacking them with IGF-1 LR3 may push pathway signaling beyond what’s needed, increasing edema, insulin resistance, and carpal tunnel symptoms without a clear additive benefit Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Glucocorticoids — These can oppose anabolic signaling and disrupt glucose control, potentially blunting the desired tissue effects while adding glycemic instability.

Vascular medications — Given the effects on endothelial biology and fluid handling, caution is warranted with antihypertensives, diuretics, and anticoagulants, though no formal studies quantify the interaction.

Supplements — Berberine, cinnamon, alpha-lipoic acid, and high-dose leucine or EAA products may further influence glucose or mTOR signaling. The risk is additive hypoglycemia rather than a direct pharmacokinetic clash.

The most common research stacks pair IGF-1 LR3 with growth hormone secretagogues (like CJC-1295/Ipamorelin or MK-677) to cover both the GH and direct IGF-1R axes. The logic is horizontal pathway coverage, but in practice this often oversaturates the PI3K-Akt-mTOR pathway and drives side effects like fluid retention, insulin resistance, and joint stiffness more than it amplifies muscle gain Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

For tissue healing, many practitioners combine IGF-1 LR3 with BPC-157 or TB-500. The rationale is that IGF-1 provides the anabolic push while BPC-157 and TB-500 support angiogenesis and cell migration. Again, formal interaction studies are lacking, and the sum of growth signals can occasionally produce unexpected tightness or edema at the injury site.

If using alongside GLP-1 agonists (e.g., semaglutide), the core conflict is goal-oriented: GLP-1s suppress appetite and body weight, while IGF-1 LR3 is typically deployed for anabolism. The combination requires careful monitoring of energy intake and glucose, as undereating with elevated IGF-1 signaling is a known recipe for hypoglycemia.

IGF-1 LR3 is not FDA-approved for any clinical indication and is consistently described in the literature as an experimental, unauthorized IGF-1 analog Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. It is distinct from approved recombinant IGF-1 products such as mecasermin (Increlex).

Outside the U.S., the European Medicines Agency, the UK’s MHRA, and Australia’s TGA have not approved IGF-1 LR3; it remains a research peptide in regulatory frameworks. Specific import rules vary by country and must be checked locally.

For athletes, IGF-1 LR3 falls under the World Anti-Doping Agency’s prohibition of growth factors and anabolic agents. It is banned at all times, both in and out of competition, and is considered a higher-risk doping substance due to its potent receptor activity Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Hypoglycemia is the most commonly reported concern. IGF-1 LR3 can suppress insulin secretion and lower blood glucose, especially when taken in a fasted state or alongside other glucose-lowering agents IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep+1. Symptoms like shakiness, sweating, and brain fog should be treated with fast-acting carbohydrates.

Fluid retention and mild swelling of the hands or face can occur, reflecting the peptide’s anabolic and sodium-retaining properties. This usually resolves after stopping the cycle.

Long-term risks are less defined. Because IGF-1 signaling can promote cell proliferation and survival, there is a theoretical concern about accelerating occult tumors or stimulating hypertrophic changes in the heart and other organs Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. No human cancer data exist for LR3 specifically, but the biology warrants caution in anyone with a history of malignancy or pre-existing hypertrophic conditions.

Contraindications include active or suspected cancer, diabetic or prediabetic states without close glucose monitoring, pregnancy, and breastfeeding. A baseline metabolic panel, fasting glucose, and HbA1c are advisable before starting a research protocol.